A Look at Amicus Therapeutics's Valuation as Profitability and Strong Guidance Signal Financial Turnaround

Amicus Therapeutics (FOLD) has reported third-quarter results showing a swing to net income after a loss just a year ago. The company also reaffirmed guidance for solid revenue growth through the rest of 2025. Investors are closely watching these signs of financial improvement.

See our latest analysis for Amicus Therapeutics.

Following these upbeat earnings, Amicus Therapeutics’ share price is up nearly 29% over the past three months, showing meaningful momentum as investors react to its swing into profitability and reiterated revenue outlook. That said, the one-year total shareholder return remains negative, reflecting lingering long-term volatility even as sentiment improves in the short run.

If Amicus’s turnaround story has your attention, this could be a good moment to discover other innovative healthcare stocks. See the full list for free.

With shares rebounding and analysts forecasting nearly 70 percent upside from current prices, investors are left to wonder if Amicus Therapeutics is attractively valued today or if the market has already taken all of its future growth into account.

Most Popular Narrative: 42.3% Undervalued

With a narrative fair value set at $15.60 and the stock last closing at $9.00, this perspective suggests significant upside is still on the table. The narrative places emphasis on powerful catalysts supporting this view.

Bullish analysts are encouraged by recent court decisions that maintained the validity of key patents, supporting the durability of Amicus’s intellectual property portfolio. Raised price targets signal optimism, with projections suggesting significant upside if key therapies remain protected from generic competition through 2037.

Read the complete narrative.

What is the secret behind this compelling valuation gap? Discover which blockbuster product assumptions and aggressive profit projections shape this narrative’s bold target. The details might just surprise you.

Result: Fair Value of $15.60 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, ongoing legal disputes or disappointing clinical trial outcomes could quickly undermine the bullish case and have a negative impact on Amicus Therapeutics’ valuation outlook.

Find out about the key risks to this Amicus Therapeutics narrative.

Build Your Own Amicus Therapeutics Narrative

If you have a different perspective or want to dig into the numbers on your own, you can craft a personalized view in just a few minutes. Do it your way

A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Amicus Therapeutics.

Looking for More Investment Ideas?

Don’t let great opportunities pass you by. Some of the most exciting stocks may be off the beaten path. Find your edge with these hand-picked themes and get ahead of the crowd:

• Spot overlooked potential by checking out these 3575 penny stocks with strong financials, where smaller companies could be gearing up for outsized growth and market attention.
• Unlock the future of medicine by scanning these 32 healthcare AI stocks focused on game changers using artificial intelligence to transform healthcare and patient outcomes.
• Secure steady income by browsing these 16 dividend stocks with yields > 3%, highlighting companies with yields over 3 percent, which may help in building reliable returns in any market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com